ReviewMedComm2022
Graphene and graphene oxide with anticancer applications: Challenges and future perspectives.
Review in MedComm, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Green-Synthesized Nanomaterials for Kidney Cancer: Current Progress and Future Perspectives.International journal of molecular sciences · 2026Review
- Dual-functional sulfonated PEEK implants via graphene oxide-mediated BMP-2 gene delivery: enhanced osteogenic and antibacterial performanceFrontiers in medicine · 2026Article
- Surface-tailored graphene nanosheets targeting PI3K/Akt signaling of breast cancer cells.Scientific reports · 2025Article
- Intratracheal instillation of graphene oxide with different diameters suppressed toll-like receptor 3-mediated lipid droplet biogenesis in lungs and livers of mice.Toxicology research · 2025Article
- Graphene Nanocomposites in the Targeting Tumor Microenvironment: Recent Advances in TME Reprogramming.International journal of molecular sciences · 2025Review
- Biosafety and Blood Compatibility of Graphene Oxide Particles in In Vitro Experiments.Materials (Basel, Switzerland) · 2025Article
- Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer.Current pharmaceutical biotechnology · 2025Review
- Combined Graphene Oxide with 2-Methoxyestradiol for Effective Anticancer Therapy in-vitro Model.International journal of nanomedicine · 2025Article
- Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.Current pharmaceutical design · 2025Review
- Paclitaxel-Loaded, Pegylated Carboxylic Graphene Oxide with High Colloidal Stability, Sustained, pH-Responsive Release and Strong Anticancer Effects on Lung Cancer A549 Cell Line.Pharmaceutics · 2024Article
- Enhancement of 5-Fluorouracil Drug Delivery in a Graphene Oxide Containing Electrospun Chitosan/Polyvinylpyrrolidone Construct.Materials (Basel, Switzerland) · 2024Article
- Recent Advancements in Gallic Acid-Based Drug Delivery: Applications, Clinical Trials, and Future Directions.Pharmaceutics · 2024Review
- Core-Tunable Dendritic Polymer: A Folate-Guided Theranostic Nanoplatform for Drug Delivery Applications.ACS omega · 2024Article
- Article
- Nanoarchitectonics and Biological Properties of Nanocomposite Thermosensitive Chitosan Hydrogels Obtained with the Use of Uridine 5'-Monophosphate Disodium Salt.International journal of molecular sciences · 2024Article
- Comparative evaluation of hesperetin-loaded graphene oxide nanosheets (Hsp-GO) as a drug delivery system for colon cancer: synthesis and anticancer efficiency assessment.Molecular biology reports · 2024Article
- [Immunogenic and toxic effects of graphene oxide nanoparticles in mouse skeletal muscles and human red blood cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Comprehensive Assessment of Graphene Oxide Nanoparticles: Effects on Liver Enzymes and Cardiovascular System in Animal Models and Skeletal Muscle Cells.Nanomaterials (Basel, Switzerland) · 2024Article
- Graphene Oxide (GO) for the Treatment of Bone Cancer: A Systematic Review and Bibliometric Analysis.Nanomaterials (Basel, Switzerland) · 2024Review
- Exploring and Anticipating the Applications of Organic Room-Temperature Phosphorescent Materials in Biomedicine and Dentistry.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graphene-based materials have shown immense pertinence for sensing/imaging, gene/drug delivery, cancer therapy/diagnosis, and tissue engineering/regenerative medicine. Indeed, the large surface area, ease of functionalization, high drug loading capacity, and reactive oxygen species induction potentials have rendered graphene- (G-) and graphene oxide (GO)-based (nano)structures promising candidates for cancer therapy applications. Various techniques namely liquid-phase exfoliation, Hummer's method, chemical vapor deposition, chemically reduced GO, mechanical cleavage of graphite, arc discharge of graphite, and thermal fusion have been deployed for the production of G-based materials. Additionally, important criteria such as biocompatibility, bio-toxicity, dispersibility, immunological compatibility, and inflammatory reactions of G-based structures need to be systematically assessed for additional clinical and biomedical appliances. Furthermore, surface properties (e.g., lateral dimension, charge, corona influence, surface structure, and oxygen content), concentration, detection strategies, and cell types are vital for anticancer activities of these structures. Notably, the efficient accumulation of anticancer drugs in tumor targets/tissues, controlled cellular uptake properties, tumor-targeted drug release behavior, and selective toxicity toward the cells are crucial criteria that need to be met for developing future anticancer G-based nanosystems. Herein, important challenges and future perspectives of cancer therapy using G- and GO-based nanosystems have been highlighted, and the recent advancements are deliberated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.